Does botulinum toxin injection site determine outcome in post-stroke plantarflexion spasticity? Comparison study of two injection sites in the gastrocnemius muscle: a randomized double-blind controlled trial
Restricted accessResearch articleFirst published online June, 2014
Does botulinum toxin injection site determine outcome in post-stroke plantarflexion spasticity? Comparison study of two injection sites in the gastrocnemius muscle: a randomized double-blind controlled trial
To determine if botulinum toxin type A injection at the proximal 2/10 and 3/10 of calf length, where the intramuscular nerve endings of the gastrocnemius muscle are densely distributed, is more efficacious in controlling plantarflexion spasticity than injection at distant sites within the same muscle.
Design:
A double-blind randomized controlled trial.
Settting:
Two rehabilitation centres.
Subjects:
Forty stroke patients were randomly allocated to two groups. Group A received injection at the proximal 2/10 and 3/10 of calf length, group B at and below the midbelly of the muscle. Both groups received 200 IU of botulinum toxin A and were followed up to eight weeks.
Main measures:
Primary variables were the surface electromyography values recorded during plantarflexion; secondary variables were the Modified Ashworth Scale, Modified Tardieu Scale, clonus scale, 10-metre walking test, ABILOCO and Functional Ambulation Categories.
Results:
At baseline, the median Modified Ashworth Scale was 2.0 (range,1+ −3.0), and there were no significant differences between the two groups in all the parameters, including spasticity. Compared to baseline, no significant differences between the two groups were detected in all the surface electromyography and clinical parameters at week 8 (P > 0.05). Both groups showed significant improvement of spasticity with a median Modified Ashworth Scale of 1+ (range, 0.0–2.0) at eight weeks.
Conclusions:
Botulinum toxin A injection was associated with a significant improvement from baseline to week 8 in both treatment groups, however, no significant difference between the 2 groups was observed, based on the electrophysiological and clinical parameters employed in this study.
HesseSKrajnikJLueckeDJahnkeMTGregoricMMauritzKH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke1996; 27: 455–460.
3.
KajiROsakoYSuyamaKMaedaTUechiYIwasakiM. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol2010; 257: 1330–1337.
4.
PittockSJMooreAPHardimanO. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis2003; 15: 289–300.
5.
BorodicGEPearceLBSmithKJosephM. Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck1992; 14: 33–37.
6.
LapatkiBGvan DijkJPvandeWarrenburgBPZwartsMJ. Botulinum toxin has an increased effect when targeted toward the muscle’s endplate zone: a high-density surface EMG guided study. Clin Neurophysiol2011; 122: 1611–1616.
7.
ShaariCMGeorgeEWuBLBillerHFSandersI. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope1991; 101: 960–964.
8.
CoersC. Structural organization of the motor nerve endings in mammalian muscle spindles and other striated muscle fibers. Am J Phys Med1959; 38: 166–175.
9.
ChristensenE. Topography of terminal motor innervation in striated muscles from stillborn infants. Am J Phys Med1959; 38: 65–78.
10.
SheverdinVAHurMSWonSYSongWCHuKSKohKS. Extra- and intramuscular nerves distributions of the triceps surae muscle as a basis for muscle resection and botulinum toxin injections. Surg Radiol Anat2009; 31: 615–621.
11.
ParratteBTatuLVuillierFDiopMMonnierG. Intramuscular distribution of nerves in the human triceps surae muscle: anatomical bases for treatment of spastic drop foot with botulinum toxin. Surg Radiol Anat2002; 24: 91–96.
12.
JuliousSA. Sample size of 12 per group rule of thumb for a pilot study. Pharmac Stat2005; 4: 287–291.
13.
KaishouXTiebinYJianningM. A randomized controlled trial to compare two botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy. Clin Rehabil2009; 23: 800–811.
14.
ChildersMKStacyMCookeDLStonningtonHH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am J Phys Med Rehabil1996; 75: 462–469.
15.
GraciesJMLugassyMWeiszDJVecchioMFlanaganSSimpsonDM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil2009; 90: 9–16 e12.
16.
MayerNHWhyteJWannstedtGEllisCA. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Arch Phys Med Rehabil2008; 89: 982–987.
17.
SloopRREscutinROMatusJAColeBAPetersonGW. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology1996; 46: 1382–1386.
18.
HermensHJBoonKLZilvoldG. The clinical use of surface EMG. Electromyogr Clin Neurophysiol1984; 24: 243–265.
19.
DunneJWGraciesJMHayesMZemanBSingerBJ. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil2012; 26: 787–797.
20.
YamWKLeungMS. Interrater reliability of Modified Ashworth Scale and Modified Tardieu Scale in children with spastic cerebral palsy. J Child Neurol2006; 21: 1031–1035.
21.
Vos-VromansDCde BieRAErdmannPGvan MeeterenNL. The responsiveness of the ten-meter walking test and other measures in patients with hemiparesis in the acute phase. Physiother Theory Pract2005; 21: 173–180.
22.
CatyGDArnouldCStoquartGGThonnardJLLejeuneTM. ABILOCO: a Rasch-built 13-item questionnaire to assess locomotion ability in stroke patients. Arch Phys Med Rehabil2008; 89: 284–290.
23.
HoldenMKGillKMMagliozziMRNathanJPiehl-BakerL. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther1984; 64: 35–40.
24.
LeeWJParkGYHanZA. Korean Version of the ABILOCO Questionnaire in the Assessment of Locomotion in Hemiplegic Stroke Patients. Ann Rehabil Med2013; 37: 72–81.
25.
SchulzKFAltmanDGMoherD. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ2010; 340: c332.
26.
SatilaHIisaloTPietikainenT. Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites. Am J Phys Med Rehabil2005; 84: 355–365; quiz 366–357, 392.
27.
HallettMGlockerFXDeuschlG. Mechanism of action of botulinum toxin. Ann Neurol1994; 36: 449–450.
28.
RestaniLNovelliEBottariD. Botulinum neurotoxin a impairs neurotransmission following retrograde transynaptic transport. Traffic2012; 13: 1083–1089.
29.
AntonucciFRossiCGianfranceschiLRossettoOCaleoM. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci2008; 28: 3689–3696.
30.
BoroojerdiBCohenLGHallettM. Effects of botulinum toxin on motor system excitability in patients with writer’s cramp. Neurology2003; 61: 1546–1550.
31.
LimECQuekAMSeetRC. Accurate targeting of botulinum toxin injections: how to and why. Parkinsonism Relat Disord2011; 17(suppl 1): S34–39.
32.
WisselJWardABErztgaardP. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med2009; 41: 13–25.
33.
GraciesJMWilsonLGandeviaSCBurkeD. Stretched position of spastic muscles aggravates their co-contraction in hemiplegic patientsAnn Neurol1997; 42: 438–439.
34.
HesseSBrandl-HesseBSeidelUDollBGregoricM. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restor Neurol Neurosci2000; 17: 1–8.
35.
TangSFHongJPMcKayWBTangCWWuPHChuNK. Modification of altered ankle motor control after stroke using focal application of botulinum toxin type A. Clin Neurol Neurosurg2012; 114: 498–501.
36.
SatilaHPietikainenTIisaloT. Botulinum toxin type A injections into the calf muscles for treatment of spastic equinus in cerebral palsy: a randomized trial comparing single and multiple injection sites. Am J Phys Med Rehabil2008; 87: 386–394.
37.
ChinTYNattrassGRSelberPGrahamHK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop2005; 25: 286–291.
38.
PicelliABonettiPFontanaC. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography. J Rehabil Med2012; 44: 450–452.
39.
SimpsonDMAlexanderDNO’BrienCF. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology1996; 46: 1306–1310.
40.
ImSHanSHChoiJH. Anatomic localization of motor points for the neuromuscular blockade of hand intrinsic muscles involved in thumb-in-palm. Am J Phys Med Rehabil2008; 87: 703–709.
